95 related articles for article (PubMed ID: 24330150)
21. Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer.
Ikeda S; Fujimori M; Shibata S; Okajima M; Ishizaki Y; Kurihara T; Miyata Y; Iseki M; Shimizu Y; Tokumoto N; Ozaki S; Asahara T
BMC Cancer; 2006 Feb; 6():31. PubMed ID: 16451736
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
23. [Use of immunohistochemistry in detecting the primary site in neoplasm metastasis].
de Almeida PC; Pestana CB
AMB Rev Assoc Med Bras; 1989; 35(3):84-7. PubMed ID: 2699378
[TBL] [Abstract][Full Text] [Related]
24. [Dipeptidyl peptidase IV (DPP IV, CD 26): a tumor marker in cytologic and histopathologic diagnosis of lesions of the thyroid gland].
Kholová I; Ryska A; Ludvíková M; Pecen L; Cáp J
Cas Lek Cesk; 2003 Mar; 142(3):167-71. PubMed ID: 12756846
[TBL] [Abstract][Full Text] [Related]
25. Molecular methods for predicting the metastatic potential of prostate cancer.
Schalken JA
Cancer Surv; 1991; 11():43-54. PubMed ID: 1726788
[TBL] [Abstract][Full Text] [Related]
26. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Jiang Z; Woda BA; Wu CL; Yang XJ
Am J Clin Pathol; 2004 Aug; 122(2):275-89. PubMed ID: 15323145
[TBL] [Abstract][Full Text] [Related]
27. Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques.
Svanholm H; Hørder M
Scand J Urol Nephrol Suppl; 1988; 107():65-70. PubMed ID: 2453920
[TBL] [Abstract][Full Text] [Related]
28. The proliferation marker Chromatin Assembly Factor-1 is of clinical value in predicting the biological behaviour of salivary gland tumours.
Staibano S; Mascolo M; Rocco A; Lo Muzio L; Ilardi G; Siano M; Pannone G; Vecchione ML; Nugnes L; Califano L; Zamparese R; Bufo P; De Rosa G
Oncol Rep; 2011 Jan; 25(1):13-22. PubMed ID: 21109952
[TBL] [Abstract][Full Text] [Related]
29. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
30. [Tumour markers in epithelial ovarian cancer].
Sparholt MH; Høgdall E; Høgdall CK
Ugeskr Laeger; 2009 Nov; 171(48):3505-9. PubMed ID: 19944049
[TBL] [Abstract][Full Text] [Related]
31. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
32. [The role of monoclonal antibodies to the epithelial membrane antigen in the diagnosis of human tumors].
Delektorskaia VV; Ermilova VD; Baryshnikov AIu; Raĭkhlin NT
Vopr Onkol; 1992; 38(5):562-71. PubMed ID: 1300755
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of markers M2A, OCT3/4, AP-2gamma, PLAP and c-KIT in the detection of extragonadal seminomas.
Biermann K; Klingmüller D; Koch A; Pietsch T; Schorle H; Büttner R; Zhou H
Histopathology; 2006 Sep; 49(3):290-7. PubMed ID: 16918976
[TBL] [Abstract][Full Text] [Related]
34. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression.
Pinho SS; Matos AJ; Lopes C; Marcos NT; Carvalheira J; Reis CA; Gärtner F
BMC Cancer; 2007 Jul; 7():124. PubMed ID: 17617904
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemistry in dermatopathology: a review of the most commonly used antibodies (part I).
Fuertes L; Santonja C; Kutzner H; Requena L
Actas Dermosifiliogr; 2013 Mar; 104(2):99-127. PubMed ID: 23062957
[TBL] [Abstract][Full Text] [Related]
36. CD56 expression of neuroendocrine neoplasms on immunophenotyping by flow cytometry: a novel diagnostic approach to fine-needle aspiration biopsy.
Farinola MA; Weir EG; Ali SZ
Cancer; 2003 Aug; 99(4):240-6. PubMed ID: 12925986
[TBL] [Abstract][Full Text] [Related]
37. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma.
Perry KD; Reynolds C; Rosen DG; Edgerton ME; T Albarracin C; Gilcrease MZ; Sahin AA; Abraham SC; Wu Y
Histopathology; 2011 Oct; 59(4):619-30. PubMed ID: 22014043
[TBL] [Abstract][Full Text] [Related]
38. PSA and PAP as immunohistochemical markers in prostate cancer.
Epstein JI
Urol Clin North Am; 1993 Nov; 20(4):757-70. PubMed ID: 7505984
[TBL] [Abstract][Full Text] [Related]
39. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
[TBL] [Abstract][Full Text] [Related]
40. [Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group].
Basuyau JP; Blanc-Vincent MP; Bidart JM; Daver A; Deneux L; Eche N; Gory-Delabaere G; Pichon MF; Riedinger JM
Bull Cancer; 2000 Oct; 87(10):723-37. PubMed ID: 11084536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
